

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 85418

Title: Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02832130 Position: Peer Reviewer Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Malaysia

Manuscript submission date: 2023-04-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-04-27 08:07

Reviewer performed review: 2023-05-02 02:40

Review time: 4 Days and 18 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Name of Journal: World Journal of Gastroenterology Manuscript Type: REVIEW Serum resistin and the risk for hepatocellular carcinoma in diabetic patients Comments: The author of this manuscript reviewed the existing literature on the possible use of resistin levels as a biomarker for HCC development and monitoring, and the possible pathways of HCC initiation due to elevated resistin and offers new perspectives on comprehending the fundamental mechanisms of HCC in diabetic patients. The subject of this manuscript is of value, but there are defects need to be modified. 1. The subtitle and capitalization of the manuscript need to be checked and revised, otherwise it may make the structure of the article unclear. 2.Does the "Prevalence of HCC in Diabetic Patients" section belong to the INTRODUCTION section. 3.Terminology abbreviation issues. INTRODUCTION Background on HCC and diabetes section:Liver cancer, particularly HCC.....Should HCC be rewritten as Hepatocellular carcinoma (HCC) here; Prevalence of HCC in Diabetic Patients section: Hepatocellular carcinoma is more...... Should "Hepatocellular carcinoma" be rewritten as HCC here; The abbreviations of "Core tip" section should also be checked. 4. The space issues: Please check and revise:.....as well as



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

their impact on glycaemic control [46, 108-110]. Although......;and angiogenesis [133, 138-140]...... 5. Diagnosis and Management of HCC in Diabetic Patients section: the Fifth paragraph: For early-stage HCC, "local therapies such as radiofrequency ablation and percutaneous ethanol injections are available...... Should TACE be included in the local therapies here, as "transarterial chemoembolization (TACE)" is a very important treatment method for patients with HCC. 6. The description of the Resistin secretion is

therapies here, as "transarterial chemoembolization (TACE)" is a very important treatment method for patients with HCC. 6. The description of the Resistin secretion is inconsistent in the text. Please check and confirm and modify. Resistin as a potential biomarker in HCC section:......Resistin is primarily generated by human macrophages and rodent adipocytes......, and INTRODUCTION section: Background on HCC and diabetes section:Resistin, a hormone secreted by adipocytes and linked to obesity and T2DM, has been connected to the HCC development and progression [27-30]......



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 85418

Title: Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05393454 Position: Peer Reviewer Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Malaysia

Manuscript submission date: 2023-04-26

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-17 06:10

Reviewer performed review: 2023-05-24 15:59

Review time: 7 Days and 9 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

1. The English need improvement since there are some grammatical and syntax errors in the manuscript. For example, the words "to the HCC" may be as "to HCC"; "be reliable" as "be a reliable"; "have being" as "have been"; "in modulation" as "in the modulation"; "of immune" as "of the immune"; "through stimulating" as "by stimulating"; "enhancement" as "the enhancement". The grammar mistakes which are not mentioned here are also to be checked and corrected properly. 2. There are some typing mistakes as well, and authors are advised to carefully proof-read the text. For example, the words "chances of" may be as "chance of"; "instance insulin" as "instance, insulin"; "that promote" as "that promotes"; "figure" as "Figure"; "advanced illness" as "advanced illnesses"; "sclinical" as "clinical"; "as well as serum resistin" as ", as well as serum resistin,"; "HCV cirrhotic" as "HCV-cirrhotic"; "levels," as "levels,"; "well established" as "well-established"; "though" as "through". The typos not mentioned here are also to be checked and corrected properly. 3. Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears the first time in the abstract and the remaining for the text and then use only the abbreviation (For



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com **https:**//www.wjgnet.com

example, Hepatocellular carcinoma (HCC), Insulin resistance (IR), FDA, etc.,). Make a word abbreviated in the article that is repeated at least three times in the text, not all words to be abbreviated. The authors may also avoid the usage of abbreviations in the sub-title. 4. The literature search should be described in detail. The authors are encouraged to include the database, search engines (like PubMed, ScienceDirect, Google scholar etc.,), the keywords used etc., which may be included since it is a review article. 5. The introduction part appears less informative about the hepatocellular carcinoma, thus this section should be indicated as detailed to understand the manuscript in clear. The authors may cite recent prevalence or incidence data about hepatocellular carcinoma and it should be at-least of 2022 or 2023. 6. The authors should improve the quality of the images (Figure 2) used in the manuscript with high resolution for better understanding. For example, the letters used are blurred and it should be rectified. 7. The limitation of the present review may be given along with conclusion or under separate heading for understanding the concepts clearly.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 85418

Title: Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05249683 Position: Editorial Board

Academic degree: BSc, MSc, PhD

Professional title: Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Malaysia

Manuscript submission date: 2023-04-26

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-17 08:27

Reviewer performed review: 2023-05-25 13:29

Review time: 8 Days and 5 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The review appears to include the effect of resistin in both hepatocellular cancer and diabetes. The paragraphs are brief and well-explained. References are used to back up the writing. Figures 1 and 2 were well-designed illustrations. The following factors must be considered: 1) On page 3 (3rd paragraph), the statement "High levels of resistin have been associated with IR, inflammation, and oxidative stress, all of which are known risk factors for HCC development [29-31]" should be revised and separated into two sentences. 2) The authors should distinguish between the titles "Resistin as a potential biomarker in HCC" on page 10 and "Serum Resistin as a Potential Clinical Biomarker for Liver Cirrhosis and Hepatocellular Carcinoma: Evidence from Clinical Studies" on page 11. 3) The number of studies in Table 1 should be increased.